AU2014231229A1 - Single high dose of MVA induces a protective immune response in neonates and infants - Google Patents
Single high dose of MVA induces a protective immune response in neonates and infants Download PDFInfo
- Publication number
- AU2014231229A1 AU2014231229A1 AU2014231229A AU2014231229A AU2014231229A1 AU 2014231229 A1 AU2014231229 A1 AU 2014231229A1 AU 2014231229 A AU2014231229 A AU 2014231229A AU 2014231229 A AU2014231229 A AU 2014231229A AU 2014231229 A1 AU2014231229 A1 AU 2014231229A1
- Authority
- AU
- Australia
- Prior art keywords
- mva
- administration
- tcid
- human
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001681 protective effect Effects 0.000 title claims abstract description 44
- 230000028993 immune response Effects 0.000 title claims abstract description 36
- 230000004044 response Effects 0.000 claims abstract description 42
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 239000000427 antigen Substances 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 241000700647 Variola virus Species 0.000 claims description 15
- 241000700629 Orthopoxvirus Species 0.000 claims description 6
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 230000036755 cellular response Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 description 72
- 241000725630 Ectromelia virus Species 0.000 description 43
- 229960005486 vaccine Drugs 0.000 description 39
- 241000700605 Viruses Species 0.000 description 33
- 230000003053 immunization Effects 0.000 description 33
- 238000002649 immunization Methods 0.000 description 33
- 230000004224 protection Effects 0.000 description 33
- 238000002255 vaccination Methods 0.000 description 28
- 206010046865 Vaccinia virus infection Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 208000007089 vaccinia Diseases 0.000 description 27
- 206010072219 Mevalonic aciduria Diseases 0.000 description 19
- 230000005867 T cell response Effects 0.000 description 19
- 201000005505 Measles Diseases 0.000 description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 238000011813 knockout mouse model Methods 0.000 description 13
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000005875 antibody response Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 108700014844 flt3 ligand Proteins 0.000 description 9
- 230000002516 postimmunization Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 231100000518 lethal Toxicity 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 208000036142 Viral infection Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000003362 replicative effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 5
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 5
- 230000033289 adaptive immune response Effects 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000725643 Respiratory syncytial virus Species 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 4
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 208000007203 infectious ectromelia Diseases 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 230000007787 long-term memory Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940127241 oral polio vaccine Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000008873 bone osteosarcoma Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229940083538 smallpox vaccine Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- XHRCFGDFESIFRG-UHFFFAOYSA-N 2-chloro-n-ethyl-n-[(2-methylphenyl)methyl]ethanamine Chemical compound ClCCN(CC)CC1=CC=CC=C1C XHRCFGDFESIFRG-UHFFFAOYSA-N 0.000 description 1
- 229940124965 ACAM2000 Drugs 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000005585 Poxviridae Infections Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000036581 Vaccinia virus Western Reserve Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940029583 inactivated polio vaccine Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000008041 oiling agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019200977A AU2019200977A1 (en) | 2013-03-15 | 2019-02-12 | Single high dose of mva induces a protective immune response in neonates and infants |
| AU2020260472A AU2020260472A1 (en) | 2013-03-15 | 2020-10-29 | Single high dose of mva induces a protective immune response in neonates and infants |
| AU2022235527A AU2022235527B2 (en) | 2013-03-15 | 2022-09-20 | Single high dose of mva induces a protective immune response in neonates and infants |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788722P | 2013-03-15 | 2013-03-15 | |
| US61/788,722 | 2013-03-15 | ||
| PCT/EP2014/000693 WO2014139687A1 (en) | 2013-03-15 | 2014-03-14 | Single high dose of mva induces a protective immune response in neonates and infants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019200977A Division AU2019200977A1 (en) | 2013-03-15 | 2019-02-12 | Single high dose of mva induces a protective immune response in neonates and infants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014231229A1 true AU2014231229A1 (en) | 2015-09-17 |
Family
ID=50389388
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014231229A Abandoned AU2014231229A1 (en) | 2013-03-15 | 2014-03-14 | Single high dose of MVA induces a protective immune response in neonates and infants |
| AU2019200977A Abandoned AU2019200977A1 (en) | 2013-03-15 | 2019-02-12 | Single high dose of mva induces a protective immune response in neonates and infants |
| AU2020260472A Abandoned AU2020260472A1 (en) | 2013-03-15 | 2020-10-29 | Single high dose of mva induces a protective immune response in neonates and infants |
| AU2022235527A Active AU2022235527B2 (en) | 2013-03-15 | 2022-09-20 | Single high dose of mva induces a protective immune response in neonates and infants |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019200977A Abandoned AU2019200977A1 (en) | 2013-03-15 | 2019-02-12 | Single high dose of mva induces a protective immune response in neonates and infants |
| AU2020260472A Abandoned AU2020260472A1 (en) | 2013-03-15 | 2020-10-29 | Single high dose of mva induces a protective immune response in neonates and infants |
| AU2022235527A Active AU2022235527B2 (en) | 2013-03-15 | 2022-09-20 | Single high dose of mva induces a protective immune response in neonates and infants |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9707291B2 (enExample) |
| EP (2) | EP2968524A1 (enExample) |
| JP (1) | JP6480875B2 (enExample) |
| KR (1) | KR102269491B1 (enExample) |
| CN (1) | CN105101993A (enExample) |
| AU (4) | AU2014231229A1 (enExample) |
| BR (1) | BR112015021781A2 (enExample) |
| CA (1) | CA2905569C (enExample) |
| EA (1) | EA034825B1 (enExample) |
| HK (1) | HK1216860A1 (enExample) |
| IL (1) | IL241059B (enExample) |
| MX (1) | MX376293B (enExample) |
| MY (1) | MY175269A (enExample) |
| SG (2) | SG10201707340XA (enExample) |
| UA (1) | UA126785C2 (enExample) |
| WO (1) | WO2014139687A1 (enExample) |
| ZA (1) | ZA201507017B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968524A1 (en) * | 2013-03-15 | 2016-01-20 | Bavarian Nordic A/S | Single high dose of mva induces a protective immune response in neonates and infants |
| WO2015136056A1 (en) | 2014-03-12 | 2015-09-17 | Bavarian Nordic A/S | Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus |
| MX2022015489A (es) * | 2020-06-10 | 2023-03-22 | Bavarian Nordic As | Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9117596D0 (en) * | 1991-08-15 | 1991-10-02 | John Gibson Lifting Gear Ltd | Pulling system |
| US5471902A (en) * | 1994-02-22 | 1995-12-05 | Athenry Enterprises Limited | Tuning system for pianos |
| US7097842B2 (en) * | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| DE20122302U1 (de) * | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| JP4801880B2 (ja) * | 2002-04-19 | 2011-10-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| NO347468B1 (no) * | 2005-02-23 | 2023-11-13 | Bavarian Nordic As | Et modifisert Vacciniavirus Ankara (MVA) for anvendelse ved immunisering. |
| WO2008028665A1 (en) * | 2006-09-08 | 2008-03-13 | Bavarian Nordic A/S | Phenotypic and genotypic differences of mva strains |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| US20120135032A1 (en) * | 2009-10-08 | 2012-05-31 | Bavarian Nordic A/S | Generation of a broad t-cell response in humans against hiv |
| US9463238B2 (en) * | 2011-12-09 | 2016-10-11 | Bavarian Nordic A/S | Recombinant poxvirus vector comprising tetanus toxin fragment C |
| EP2864487B1 (en) * | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014019718A1 (en) * | 2012-08-01 | 2014-02-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
| EP2968524A1 (en) * | 2013-03-15 | 2016-01-20 | Bavarian Nordic A/S | Single high dose of mva induces a protective immune response in neonates and infants |
-
2014
- 2014-03-14 EP EP14713036.3A patent/EP2968524A1/en not_active Ceased
- 2014-03-14 BR BR112015021781A patent/BR112015021781A2/pt not_active Application Discontinuation
- 2014-03-14 JP JP2015561981A patent/JP6480875B2/ja active Active
- 2014-03-14 MY MYPI2015703045A patent/MY175269A/en unknown
- 2014-03-14 CN CN201480015857.9A patent/CN105101993A/zh active Pending
- 2014-03-14 UA UAA201509740A patent/UA126785C2/uk unknown
- 2014-03-14 SG SG10201707340XA patent/SG10201707340XA/en unknown
- 2014-03-14 MX MX2015011388A patent/MX376293B/es active IP Right Grant
- 2014-03-14 WO PCT/EP2014/000693 patent/WO2014139687A1/en not_active Ceased
- 2014-03-14 US US14/776,881 patent/US9707291B2/en active Active
- 2014-03-14 CA CA2905569A patent/CA2905569C/en active Active
- 2014-03-14 HK HK16104937.0A patent/HK1216860A1/zh unknown
- 2014-03-14 AU AU2014231229A patent/AU2014231229A1/en not_active Abandoned
- 2014-03-14 EA EA201591803A patent/EA034825B1/ru not_active IP Right Cessation
- 2014-03-14 EP EP20163606.5A patent/EP3708187A1/en active Pending
- 2014-03-14 KR KR1020157029515A patent/KR102269491B1/ko active Active
- 2014-03-14 SG SG11201507192SA patent/SG11201507192SA/en unknown
-
2015
- 2015-09-02 IL IL241059A patent/IL241059B/en active IP Right Grant
- 2015-09-21 ZA ZA2015/07017A patent/ZA201507017B/en unknown
-
2019
- 2019-02-12 AU AU2019200977A patent/AU2019200977A1/en not_active Abandoned
-
2020
- 2020-10-29 AU AU2020260472A patent/AU2020260472A1/en not_active Abandoned
-
2022
- 2022-09-20 AU AU2022235527A patent/AU2022235527B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015021781A2 (pt) | 2017-07-18 |
| KR102269491B1 (ko) | 2021-06-25 |
| CN105101993A (zh) | 2015-11-25 |
| WO2014139687A1 (en) | 2014-09-18 |
| SG11201507192SA (en) | 2015-10-29 |
| AU2020260472A1 (en) | 2020-11-26 |
| EA201591803A1 (ru) | 2016-02-29 |
| CA2905569C (en) | 2023-07-25 |
| MY175269A (en) | 2020-06-17 |
| UA126785C2 (uk) | 2023-02-08 |
| US9707291B2 (en) | 2017-07-18 |
| ZA201507017B (en) | 2018-12-19 |
| IL241059B (en) | 2020-10-29 |
| KR20150129027A (ko) | 2015-11-18 |
| AU2019200977A1 (en) | 2019-02-28 |
| HK1216860A1 (zh) | 2016-12-09 |
| SG10201707340XA (en) | 2017-10-30 |
| IL241059A0 (en) | 2015-11-30 |
| CA2905569A1 (en) | 2014-09-18 |
| MX376293B (es) | 2025-03-07 |
| MX2015011388A (es) | 2016-02-03 |
| EP3708187A1 (en) | 2020-09-16 |
| EA034825B1 (ru) | 2020-03-25 |
| AU2022235527B2 (en) | 2023-10-26 |
| AU2022235527A1 (en) | 2022-10-13 |
| JP2016514114A (ja) | 2016-05-19 |
| EP2968524A1 (en) | 2016-01-20 |
| US20160030551A1 (en) | 2016-02-04 |
| JP6480875B2 (ja) | 2019-03-13 |
| NZ711569A (en) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022235527B2 (en) | Single high dose of mva induces a protective immune response in neonates and infants | |
| AU2003239805B2 (en) | Modified vaccinia virus ankara for the vaccination of neonates | |
| AU2004276486B2 (en) | Modified vaccinia virus ankara (MVA) mutant and use thereof | |
| CN107454848B (zh) | 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物 | |
| CA2676809C (en) | Immediate protection against pathogens via mva | |
| Giacalone et al. | Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus | |
| EP3116541B1 (en) | Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus | |
| Cheminay et al. | A single vaccination with non-replicating MVA at birth induces both immediate and long-term protective immune responses | |
| NZ711569B2 (en) | Single high dose of mva induces a protective immune response in neonates and infants | |
| Bissa et al. | Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |